Trials / Unknown
UnknownNCT04493515
Oral Oxytocin's Effects on Attention Control
Oral Oxytocin's Effects on Attention Control: An Eye-tracking Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- University of Electronic Science and Technology of China · Academic / Other
- Sex
- Male
- Age
- 18 Years – 30 Years
- Healthy volunteers
- Accepted
Summary
The main aim of the study is to investigate whether orally administered oxytocin (24IU) could modulate attention control using a social-emotional saccade/antisaccade eye-tracking paradigm.
Detailed description
Numerous studies have reported the effect of intranasally administered oxytocin on attentional processing including stimulus-driven bottom-up processing and top-down goal-directed inhibitory control. However, it is unclear whether the functional effects are mediated by the peptide directly entering the brain or indirectly via raising peripheral concentrations. One possible method of producing a similar pattern of increased peripheral oxytocin concentrations but without the possibility of direct entry into the brain would be to administer the peptide lingually. In the present double-blind, between-subject, placebo-controlled study, 80 healthy male subjects will be recruited and receive either oxytocin (24IU) or placebo control administered orally (lingual). 45 minutes after treatment subjects are required to complete a social-emotional saccade/antisaccade eye-tracking paradigm. This paradigm uses social (happy, sad, angry, fear, and neutral faces) as well as non-social (oval shapes) stimuli to explore social- and emotion-specific effects of orally administered oxytocin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral Oxytocin | Administration of oxytocin orally (24 IU) |
| DRUG | Oral Placebo | Administration of placebo orally (24 IU) |
Timeline
- Start date
- 2020-07-28
- Primary completion
- 2020-12-31
- Completion
- 2021-12-31
- First posted
- 2020-07-30
- Last updated
- 2020-07-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04493515. Inclusion in this directory is not an endorsement.